ArTS Archivio della ricerca di Trieste

ROVIELLO, GIANDOMENICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.661
EU - Europa 3.857
AS - Asia 3.386
SA - Sud America 438
Continente sconosciuto - Info sul continente non disponibili 303
AF - Africa 75
OC - Oceania 16
Totale 16.736
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.536
PL - Polonia 1.722
SG - Singapore 1.262
CN - Cina 777
IT - Italia 556
HK - Hong Kong 354
SE - Svezia 349
BR - Brasile 340
VN - Vietnam 329
DE - Germania 200
FR - Francia 157
FI - Finlandia 152
RU - Federazione Russa 131
UA - Ucraina 129
KR - Corea 123
GB - Regno Unito 118
TR - Turchia 116
IN - India 94
BD - Bangladesh 84
IE - Irlanda 78
CA - Canada 74
BG - Bulgaria 72
NL - Olanda 56
AR - Argentina 36
JP - Giappone 34
ES - Italia 31
IQ - Iraq 31
MX - Messico 28
MA - Marocco 24
MY - Malesia 22
ID - Indonesia 21
BE - Belgio 18
PK - Pakistan 18
EC - Ecuador 17
IL - Israele 15
SA - Arabia Saudita 15
AT - Austria 14
CH - Svizzera 12
CO - Colombia 11
JO - Giordania 11
AE - Emirati Arabi Uniti 10
AU - Australia 10
GR - Grecia 10
PH - Filippine 10
TN - Tunisia 10
CL - Cile 9
KE - Kenya 9
NP - Nepal 9
TW - Taiwan 9
VE - Venezuela 9
IR - Iran 8
RO - Romania 8
DZ - Algeria 7
EG - Egitto 7
UZ - Uzbekistan 7
ZA - Sudafrica 7
NZ - Nuova Zelanda 6
PE - Perù 6
PT - Portogallo 6
TH - Thailandia 6
CZ - Repubblica Ceca 5
HN - Honduras 5
JM - Giamaica 5
MD - Moldavia 5
PY - Paraguay 5
LT - Lituania 4
NO - Norvegia 4
OM - Oman 4
SI - Slovenia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AO - Angola 3
AZ - Azerbaigian 3
BO - Bolivia 3
DK - Danimarca 3
LB - Libano 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
CG - Congo 2
CR - Costa Rica 2
EE - Estonia 2
ET - Etiopia 2
GA - Gabon 2
GE - Georgia 2
GT - Guatemala 2
HU - Ungheria 2
KG - Kirghizistan 2
RS - Serbia 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
BB - Barbados 1
BH - Bahrain 1
BS - Bahamas 1
BZ - Belize 1
GY - Guiana 1
HR - Croazia 1
IS - Islanda 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LV - Lettonia 1
Totale 16.428
Salva come PNG Salva come JPEG
Città #
Warsaw 1.646
Fairfield 1.006
Ashburn 1.003
Singapore 826
Woodbridge 605
Houston 527
Wilmington 446
Seattle 432
Chandler 424
Ann Arbor 401
Cambridge 385
Hong Kong 341
San Jose 332
Beijing 223
Santa Clara 201
Jacksonville 187
Council Bluffs 170
Trieste 164
Princeton 144
Boardman 125
Seoul 110
Chicago 109
Columbus 109
Ho Chi Minh City 97
Izmir 96
Dallas 89
Los Angeles 86
Helsinki 83
Dublin 78
Hefei 76
Lauterbourg 74
Sofia 71
Moscow 63
New York 59
Zgierz 59
San Diego 56
Hanoi 54
Milan 51
Munich 51
The Dalles 49
Frankfurt am Main 43
Buffalo 38
Dearborn 37
Dong Ket 34
Bremen 32
Phoenix 28
London 26
São Paulo 26
Redwood City 25
Tokyo 23
Atlanta 22
Orem 22
Turku 21
Tianjin 20
Mumbai 19
Nuremberg 19
Shanghai 19
Casablanca 17
San Francisco 17
Toronto 17
Brussels 16
Dongguan 16
Guangzhou 16
Chennai 15
Miano 15
Lappeenranta 14
Rome 14
Da Nang 13
Denver 13
Duino-Aurisina 13
Falls Church 13
Hangzhou 13
Nanjing 13
Amsterdam 12
Des Moines 12
Hamilton 12
Boston 11
Kunming 11
Montegaldella 11
Norwalk 11
Poplar 11
Rio de Janeiro 11
Amman 10
Düsseldorf 10
Jinan 10
Lahore 10
Montreal 10
Redondo Beach 10
Tel Aviv 10
Brasília 9
Changsha 9
Fremont 9
Genoa 9
Shenzhen 9
Udine 9
Brooklyn 8
Decatur 8
Guayaquil 8
Haiphong 8
Madrid 8
Totale 12.063
Salva come PNG Salva come JPEG
Nome #
Advances in systemic therapy for metastatic breast cancer: future perspectives 430
PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene 407
Isolated testicular metastasis from prostate cancer 385
Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer 377
Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma 374
Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma 373
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 359
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer 355
Bevacizumab in small cell lung cancer 353
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 345
Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials 338
Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma 314
Corticosteroid switch after progression on abiraterone acetate plus prednisone 312
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma 294
Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer 292
Apatinib for the treatment of gastric cancer 287
Advances in systemic therapy for malignant mesothelioma: Future perspectives 283
Lenvatinib for the treatment of renal cell carcinoma 273
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy 271
The prognostic value of PI3K mutational status in breast cancer: A meta-analysis 250
Immune checkpoint inhibitors in pre-treated gastric cancer patients: Results from a literature-based meta-analysis 243
Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis 242
The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials 238
Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter? 234
Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer? 232
Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer 227
Tumour Infiltrating Lymphocytes and Immune-Related Genes as Predictors of Outcome in Pancreatic Adenocarcinoma 226
Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives (Medical Oncology, (2017), 34, 7, (119), 10.1007/s12032-017-0975-5) 223
Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? 221
Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies before and after Chemotherapy 217
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination with Eribulin in Triple-Negative Breast Cancers 212
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer 211
Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer? 208
Different efficacy of ramucirumab in patients with metastatic gastric and gastroesophageal junction cancer according to ECOG performance status 204
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer 201
A Phase II study of olaparib in breast cancer patients: Biological evaluation from a 'window of opportunity' trial 196
Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials 193
Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer 192
Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer 186
Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: A literature-based meta-analysis of randomized trials 185
Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer? 180
Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel 177
Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience 174
EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience 171
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer 165
Is there a place for bevacizumab in patients with extensive-stage small cell lung cancer? 163
Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis 163
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials 162
Familial aggregation of gastric cancer with microsatellite instability** 162
Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis 161
Avelumab in gastric cancer 159
Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis 159
Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis 154
No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials 153
Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials 152
Apatinib in metastatic gastric cancer: Can paclitaxel make the difference? 151
Single Center Experience on Anatomy-and Histopathology-Based Gastric Cancer Molecular Classification 148
Surgical management of advanced gastric cancer: An evolving issue 145
Is it time for everolimus-based combination in castration-resistant prostate cancer? 141
Neoadjuvant chemotherapy and radical radiotherapy associated with cetuximab for laryngeal cancer in a pancreas and renal recipient 140
Expanding treatment options for metastatic gastric cancer 138
Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature 138
Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis 137
Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies 137
New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials 137
Is the Gleason score the driver for the treatment decision-making of patients with castration-resistant prostate cancer in the new era of the anti-androgenic therapies? 136
Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment 135
Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer 134
Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives 132
Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033 129
Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis 127
Cancer management during the COVID-19 world pandemic 125
Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer 123
Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035: Corticosteroid-associated Adverse Events in Elderly Patients 118
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials 110
Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: An evolving issue 107
Current Trends in Liquid Biopsy Tracking Resistance in Molecular Breast Cancer-Targeted Therapies 93
Immune-gene signature: A new tool for patient selection for checkpoint inhibitors? 90
P53 antibodies as a diagnostic marker for cancer: A meta-analysis 85
The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study 76
Effects of Whole Pelvic Radiotherapy on the Distribution of Lymphocyte Subpopulations in Prostate Cancer Patients 71
New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When 63
DNA repair deficiency as circulating biomarker in prostate cancer 52
Totale 16.736
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.250
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.250
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022704 0 0 58 40 8 70 53 33 130 118 61 133
2022/20231.260 109 145 131 185 113 213 14 104 160 14 46 26
2023/2024773 36 83 45 56 34 74 141 153 2 42 50 57
2024/20252.227 27 200 377 134 171 294 101 85 261 215 189 173
2025/20264.114 415 195 181 341 405 345 601 148 405 666 218 194
2026/2027535 164 209 162 0 0 0 0 0 0 0 0 0
Totale 16.736